Guggenheim initiated coverage on Genelux with a new price target
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $8.00 | Buy | Guggenheim |
| 8/28/2024 | $10.00 | Buy | ROTH MKM |
| 11/27/2023 | $35.00 | Buy | H.C. Wainwright |
| 9/12/2023 | $40.00 | Buy | Maxim Group |
| 2/15/2023 | $10.00 | Speculative Buy | The Benchmark Company |
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial results and business updates. "Our pr
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering. The net proceeds from the offering are to be used for working capital and for general corporate purp
– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%. – Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ranging between 24% to 29.2%. – Data are supportive of Olvi-Vec being a platinum resensitizing agent beyond ovarian cancer and, consistent with earlier studies, being systemically administered in multiple solid tumo
4 - GENELUX Corp (0001231457) (Issuer)
3 - GENELUX Corp (0001231457) (Issuer)
4/A - GENELUX Corp (0001231457) (Issuer)
SC 13G - GENELUX Corp (0001231457) (Subject)
SC 13G/A - GENELUX Corp (0001231457) (Subject)
SC 13G - GENELUX Corp (0001231457) (Subject)
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt's financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux," said Thomas Zindrick, President, CEO and Chairman of the Board. "His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec." Mr. Pulisic is an ac
Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00
ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00
H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00
Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
S-8 - GENELUX Corp (0001231457) (Filer)
10-K - GENELUX Corp (0001231457) (Filer)
424B5 - GENELUX Corp (0001231457) (Filer)